SS-31 (Elamipretide)

Mechanism of action

SS-31 (elamipretide, formerly Bendavia, development code MTP-131) is a small synthetic tetrapeptide (D-Arg-2',6'-dimethyl-Tyr-Lys-Phe-NH₂) developed by Hazel Szeto's laboratory at Weill Cornell Medical College as part of a systematic effort to develop small mitochondria-penetrant peptides addressing cardiolipin biology. The molecular design combines four essential features. First, the alternating aromatic-cationic amino acid architecture confers cell membrane penetration through a receptor-independent mechanism that allows the compound to enter cells without transporter dependence. Second, the D-arginine substitution at the N-terminus and the 2',6'-dimethyl-tyrosine at position 2 confer proteolytic stability against exopeptidase and endopeptidase degradation. Third, the two aromatic residues (dimethyl-tyrosine and phenylalanine) enable strong non-covalent interactions with cardiolipin's four fatty-acyl chains. Fourth, the two cationic residues (arginine and lysine) mediate selective partitioning to the inner mitochondrial membrane, which carries the physiologically largest negative electrical potential of any cellular compartment (~-180 mV inside). On entry to the cell, SS-31 selectively accumulates in the inner mitochondrial membrane through its cationic-and-aromatic architecture, achieving mitochondrial concentrations approximately 1000-fold higher than cytoplasmic concentrations. Within the inner membrane, SS-31 binds cardiolipin non-covalently through both electrostatic (cationic-anionic) and aromatic-hydrophobic interactions. The bound state stabilises cardiolipin against oxidative peroxidation, preserves cardiolipin's role in binding and organising the respiratory chain supercomplexes (I, III, IV, and ATP synthase), and maintains the cristae membrane folding that is essential for high-efficiency oxidative phosphorylation. Downstream of cardiolipin binding, SS-31 preserves ATP production efficiency, reduces mitochondrial ROS generation, prevents cytochrome c release from cristae junctions (blocking apoptotic commitment), and maintains mitochondrial membrane potential during ischaemic or oxidative-stress challenges. The mechanism is distinct from receptor-mediated pharmacology — SS-31 does not bind any conventional receptor and does not activate any signalling cascade in the conventional sense. Rather, it produces effects through direct structural stabilisation of the cardiolipin-enriched inner membrane environment. The mitochondria-targeted mechanism produces broad tissue-effect potential because mitochondrial dysfunction is a feature of many degenerative conditions. Pre-clinical work has documented SS-31 effects in cardiac ischaemia-reperfusion (reduced infarct size), heart failure (improved cardiac function), primary mitochondrial disease (improved muscle bioenergetics in mtDNA-mutation-associated myopathy), retinal degeneration (protection of retinal pigment epithelium in AMD models), Barth syndrome (partial reversal of tafazzin-deficiency-associated cardiolipin remodelling defects), sarcopenia (improved muscle function in aged mice), and acute kidney injury (renal protection in ischaemic and toxic AKI models). Clinical translation has been broad but has produced mixed results across multiple Phase II and Phase III programmes. The EMBRACE trial in ST-elevation myocardial infarction did not meet its primary endpoint; the PROGRESS trial in HFpEF showed mixed signals; the MMPOWER-3 Phase III trial in primary mitochondrial myopathy did not meet its primary endpoint though showed secondary-endpoint signals; the TAZPOWER trial in Barth syndrome showed cardiac function improvements; the ReCLAIM trials in dry AMD have shown mixed signals with continuing analysis. The clinical-development trajectory is complicated by the diversity of mechanistically-relevant indications and the challenges of designing Phase III trials for mitochondrial-dysfunction endpoints, but Stealth BioTherapeutics (the compound's sponsor) continues clinical development in select indications.

SS-31 (elamipretide) selectively partitions into the inner mitochondrial membrane at concentrations approximately 1000-fold above cytoplasmic levels through its alternating aromatic-cationic peptide architecture — enabling receptor-independent cell membrane penetration followed by cardiolipin-binding mitochondrial targeting. The compound is the first pharmacological tool to directly stabilise cardiolipin and cristae architecture, distinguishing it mechanistically from all other mitochondrial-targeted research compounds (Zhao et al., J Biol Chem 2004).

— Notable finding

Research history

SS-31 originated in the systematic peptide-medicinal-chemistry work of Hazel Szeto's laboratory at Cornell/Weill Cornell Medical College across the late 1990s and early 2000s, part of the broader Szeto-Schiller peptide research programme exploring cell-permeable mitochondria-targeted peptides. The 'SS' prefix reflects the Szeto-Schiller collaboration (Peter Schiller at the Clinical Research Institute of Montreal contributed to the early medicinal chemistry). The compound was systematically optimised through structure-activity analysis of the alternating aromatic-cationic peptide architecture that enables receptor-independent cell membrane penetration and mitochondrial targeting. Early pre-clinical characterisation established the cardiolipin-binding mechanism and the broad cytoprotective phenotype across ischaemia-reperfusion, mitochondrial dysfunction, and oxidative stress models. Stealth BioTherapeutics (originally Stealth Peptides) was founded to advance SS-31 clinical development, entering Phase II clinical development in the early 2010s under the code name Bendavia. Clinical development has been unusually broad — Stealth BioTherapeutics has pursued Phase II and Phase III trials across multiple diverse indications reflecting the broad mechanistic relevance of mitochondrial dysfunction: EMBRACE (ST-elevation MI, Phase III, did not meet primary endpoint), PROGRESS (HFpEF, Phase II, mixed signals), MMPOWER-3 (primary mitochondrial myopathy, Phase III, did not meet primary endpoint), TAZPOWER (Barth syndrome, Phase II/III, cardiac function improvements), and ReCLAIM (dry AMD, ongoing Phase III programme). The mixed clinical results have complicated regulatory approval but not eliminated commercial development interest. As of 2026, elamipretide holds no FDA, EMA, or MHRA marketing authorisation. Stealth BioTherapeutics has continued development in select indications including Barth syndrome (where the compassionate-use experience and TAZPOWER data are more supportive) and dry AMD. The compound is available for research purposes through research-chemical suppliers as SS-31; clinical-trial-grade elamipretide is Stealth's proprietary supply. The SS-31/elamipretide clinical-development experience has been influential in the broader mitochondrial-medicine field, both for demonstrating that mitochondria-targeted peptide pharmacology is clinically tractable and for illustrating the substantial challenges of designing Phase III trials for mitochondrial-dysfunction indications where clinical endpoints are often heterogeneous.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

SS-31 (elamipretide) has one of the largest clinical-trial safety datasets of any compound on this site outside the licensed pharmaceuticals, accumulated through the Stealth BioTherapeutics clinical programme spanning multiple Phase II and Phase III trials. The reported adverse-event profile is favourable: mild-to-moderate injection-site reactions (erythema, transient nodules, occasional pain) are the most common; occasional mild headache, nausea, or fatigue; rare reports of hypersensitivity events. No clinically significant changes in routine haematology, biochemistry, or vital signs have been documented at therapeutic doses in the Phase III trial data. The favourable safety profile is consistent with the mechanism — SS-31's cardiolipin-binding action is a structural stabilisation effect on mitochondrial membranes without engagement of conventional receptors or signalling cascades that would typically produce off-target pharmacology. The tetrapeptide's small size limits immunogenicity risk; anti-drug antibodies have not been a significant issue in the clinical trials. Theoretical safety considerations centre on the chronic-dosing pharmacology of sustained cardiolipin binding. Because cardiolipin is essential to normal mitochondrial function, complete or excessive stabilisation could theoretically impair normal mitochondrial dynamics (fission-fusion cycles, mitochondrial biogenesis in response to demand). The pre-clinical and clinical data have not surfaced signals consistent with this theoretical concern, but chronic dosing pharmacology is incompletely characterised beyond the Phase III trial durations. Specific patient populations may have different risk profiles. Primary mitochondrial disease patients may have altered basal mitochondrial function that affects SS-31 pharmacology in ways not fully characterised. Elderly subjects with heart failure or renal disease may have altered pharmacokinetics. No serious drug-related adverse events have been documented at standard therapeutic doses across the Phase III trial programme. The compound's safety profile has been consistently favourable across the varying clinical-trial contexts.

UK regulatory status

SS-31 (elamipretide) is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. Multiple Phase II and Phase III trials have been conducted but none has yet supported regulatory approval, largely due to primary-endpoint failures in the pivotal trials. It is not a controlled substance under the Misuse of Drugs Act 1971. Research-grade material is available from research-chemical suppliers for legitimate pre-clinical and academic research use; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration of SS-31 to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. UK access to elamipretide through Stealth BioTherapeutics clinical trials may be available through UK trial sites participating in ongoing Phase III programmes (particularly Barth syndrome and dry AMD contexts). Individual compassionate-use access has been arranged in select Barth syndrome contexts internationally; UK compassionate use is theoretically possible through the specials framework. SS-31 is not currently on the WADA Prohibited List. Its cardiolipin-targeting mechanism does not fall within any current WADA category, though athletes should verify the current annual Prohibited List. For animal research under ASPA, SS-31 work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

Frequently asked questions